CRESCITA THERAPEUTICS INC (CTX.CA) Fundamental Analysis & Valuation

TSX:CTX • CA2258471028

Current stock price

0.75 CAD
+0.01 (+1.35%)
Last:

This CTX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CTX.CA Profitability Analysis

1.1 Basic Checks

  • CTX had negative earnings in the past year.
  • In the past year CTX had a positive cash flow from operations.
  • In the past 5 years CTX reported 4 times negative net income.
  • In multiple years CTX reported negative operating cash flow during the last 5 years.
CTX.CA Yearly Net Income VS EBIT VS OCF VS FCFCTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M -15M

1.2 Ratios

  • With a decent Return On Assets value of -0.45%, CTX is doing good in the industry, outperforming 70.97% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -0.59%, CTX is in the better half of the industry, outperforming 74.19% of the companies in the same industry.
Industry RankSector Rank
ROA -0.45%
ROE -0.59%
ROIC N/A
ROA(3y)-7.05%
ROA(5y)-4.39%
ROE(3y)-9.51%
ROE(5y)-5.97%
ROIC(3y)N/A
ROIC(5y)N/A
CTX.CA Yearly ROA, ROE, ROICCTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • CTX's Gross Margin of 52.60% is fine compared to the rest of the industry. CTX outperforms 70.97% of its industry peers.
  • CTX's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-5.59%
CTX.CA Yearly Profit, Operating, Gross MarginsCTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CTX.CA Health Analysis

2.1 Basic Checks

  • CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CTX has less shares outstanding
  • CTX has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CTX has an improved debt to assets ratio.
CTX.CA Yearly Shares OutstandingCTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
CTX.CA Yearly Total Debt VS Total AssetsCTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • CTX has an Altman-Z score of 0.16. This is a bad value and indicates that CTX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.16, CTX is in line with its industry, outperforming 48.39% of the companies in the same industry.
  • CTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Altman-Z 0.16
ROIC/WACCN/A
WACC8.6%
CTX.CA Yearly LT Debt VS Equity VS FCFCTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 3.33 indicates that CTX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 3.33, CTX belongs to the best of the industry, outperforming 80.65% of the companies in the same industry.
  • CTX has a Quick Ratio of 2.33. This indicates that CTX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 2.33, CTX belongs to the best of the industry, outperforming 83.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 2.33
CTX.CA Yearly Current Assets VS Current LiabilitesCTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CTX.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 95.91% over the past year.
  • CTX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.85%.
  • The Revenue has been growing slightly by 6.19% on average over the past years.
EPS 1Y (TTM)95.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-355.29%
Revenue 1Y (TTM)7.85%
Revenue growth 3Y-3.54%
Revenue growth 5Y6.19%
Sales Q2Q%-13.72%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTX.CA Yearly Revenue VS EstimatesCTX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

2

4. CTX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • CTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTX.CA Price Earnings VS Forward Price EarningsCTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • CTX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CTX is cheaper than 61.29% of the companies in the same industry.
  • CTX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CTX is cheaper than 64.52% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.86
EV/EBITDA 11.93
CTX.CA Per share dataCTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTX.CA Dividend Analysis

5.1 Amount

  • CTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTX.CA Fundamentals: All Metrics, Ratios and Statistics

CRESCITA THERAPEUTICS INC

TSX:CTX (4/23/2026, 7:00:00 PM)

0.75

+0.01 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31
Earnings (Next)05-13
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.94%
Ins Owner ChangeN/A
Market Cap13.96M
Revenue(TTM)21.12M
Net Income(TTM)-92.00K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.66
P/FCF 18.86
P/OCF 13.01
P/B 0.9
P/tB 0.99
EV/EBITDA 11.93
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY5.3%
OCF(TTM)0.06
OCFY7.69%
SpS1.13
BVpS0.84
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.45%
ROE -0.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.6%
FCFM 3.5%
ROA(3y)-7.05%
ROA(5y)-4.39%
ROE(3y)-9.51%
ROE(5y)-5.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-5.59%
F-Score8
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Debt/EBITDA 0
Cap/Depr 22.19%
Cap/Sales 1.58%
Interest Coverage N/A
Cash Conversion 224.01%
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 2.33
Altman-Z 0.16
F-Score8
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)39.26%
Cap/Depr(5y)31.76%
Cap/Sales(3y)2.8%
Cap/Sales(5y)2.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-355.29%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.85%
Revenue growth 3Y-3.54%
Revenue growth 5Y6.19%
Sales Q2Q%-13.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y70.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.95%
FCF growth 3YN/A
FCF growth 5Y-33.17%
OCF growth 1Y-60.62%
OCF growth 3YN/A
OCF growth 5Y-28.17%

CRESCITA THERAPEUTICS INC / CTX.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTX.CA.


What is the valuation status of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

ChartMill assigns a valuation rating of 2 / 10 to CRESCITA THERAPEUTICS INC (CTX.CA). This can be considered as Overvalued.


Can you provide the profitability details for CRESCITA THERAPEUTICS INC?

CRESCITA THERAPEUTICS INC (CTX.CA) has a profitability rating of 2 / 10.


Can you provide the financial health for CTX stock?

The financial health rating of CRESCITA THERAPEUTICS INC (CTX.CA) is 8 / 10.